Source: https://regulations.justia.com/regulations/fedreg/2019/11/29/2019-25919.html
Timestamp: 2020-08-10 12:48:43
Document Index: 537656670

Matched Legal Cases: ['art 312', 'art 601', 'art 601', 'art 312', 'art 601', 'art 601']

Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability, 65822-65823 [2019-25919] :: Food And Drug Administration :: Department Of Health And Human Services :: Regulation Tracker :: Justia
Justia Regulation Tracker Department Of Health And Human Services Food And Drug Administration Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability, 65822-65823 [2019-25919]
Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability, 65822-65823 [2019-25919]
Download as PDF 65822 Federal Register / Vol. 84, No. 230 / Friday, November 29, 2019 / Notices Application No. Drug Applicant ANDA 077523 ............................. Fluconazole for Oral Suspension, 50 mg/5 mL and 200 mg/5 mL. ANDA 078772 ............................. Epinephrine and Lidocaine HCl, 0.01 mg/mL; 2% and 0.02 mg/mL; 2%. Articaine HCl and Epinephrine Bitartrate Injection, 4%; EQ 0.017 mg base/1.7 mL, 4%; EQ 0.01 mg base/mL. Norethindrone Acetate Tablets, 5 mg ......................... IVAX Pharmaceuticals, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044. Hospira, Inc. ANDA 079138 ............................. ANDA 204236 ............................. ANDA 204421 ............................. Tramadol HCl Extended-Release Tablets, 100 mg, 200 mg, and 300 mg. Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of December 30, 2019. Approval of each entire application is withdrawn, including any strengths or products inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on December 30, 2019 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: November 25, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019–25901 Filed 11–27–19; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2019–D–5255] Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ‘‘Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products.’’ The purpose of this draft guidance is to provide recommendations to applicants khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 16:49 Nov 27, 2019 Jkt 250001 Do. Aurobindo Pharma Ltd., 279 Princeton-Hightstown Rd., East Windsor, NJ 08520. Do. regarding whether and when comparative clinical immunogenicity studies may be needed to support licensure of proposed biosimilar and interchangeable recombinant human insulins, recombinant human insulin mix products, and recombinant insulin analog products that are intended for the treatment of patients with Type 1 or Type 2 diabetes mellitus. Submit either electronic or written comments on the draft guidance by January 28, 2020 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. DATES: You may submit comments on any guidance at any time as follows: ADDRESSES: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2019–D–5255 for ‘‘Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products.’’ Received comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you E:\FR\FM\29NON1.SGM 29NON1 Federal Register / Vol. 84, No. 230 / Friday, November 29, 2019 / Notices must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993– 0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document. FOR FURTHER INFORMATION CONTACT: Sandra Benton, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 1132, Silver Spring, MD 20993, 301–796– 1042; sandra.benton@fda.hhs.gov. SUPPLEMENTARY INFORMATION: khammond on DSKJM1Z7X2PROD with NOTICES I. Background FDA is announcing the availability of a draft guidance for industry entitled ‘‘Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products.’’ The purpose of this draft guidance is to provide recommendations to applicants regarding whether and when comparative clinical immunogenicity studies may be needed to support licensure of proposed biosimilar and interchangeable recombinant human insulins, recombinant human insulin mix products, and recombinant insulin analog products that are intended for the treatment of patients with Type 1 or Type 2 diabetes mellitus (collectively referred to as ‘‘insulin products’’). Section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) requires that on March VerDate Sep<11>2014 16:49 Nov 27, 2019 Jkt 250001 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355) will be deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (42 U.S.C. 262). Although the majority of therapeutic biological products have been licensed under section 351 of the PHS Act, some protein products historically have been approved under section 505 of the FD&C Act. The BPCI Act clarified the statutory authority under which certain protein products will be regulated by amending the definition of a ‘‘biological product’’ in section 351(i) of the PHS Act to include a ‘‘protein (except any chemically synthesized polypeptide),’’ and describing procedures for submission of a marketing application for certain ‘‘biological products.’’ The biological products affected by this transition include insulin products. On March 23, 2020, the approved new drug applications (NDAs) for insulin products will be deemed to be licenses under section 351(a) of the PHS Act. Such deemed BLAs will then be available to be used as reference products by applicants seeking licensure of proposed biosimilar and interchangeable insulin products under section 351(k) of the PHS Act. This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on ‘‘Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products.’’ It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. II. Paperwork Reduction Act of 1995 This draft guidance refers to information collection provisions that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. 3501–3521). The submission of an investigational new drug application is covered under 21 CFR part 312 and approved under OMB control number 0910–0014. The submission of a BLA under section 351(a) of the PHS Act is covered under 21 CFR part 601 and approved under OMB control number 0910–0338. The submission of a BLA under section 351(k) of the PHS Act is covered under 21 CFR part 601 and approved under OMB control number 0910–0719. PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 65823 III. Electronic Access Persons with access to the internet may obtain the draft guidance at either https://www.fda.gov/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/default.htm or https:// www.regulations.gov. Dated: November 21, 2019. Brett P. Giroir, Acting Commissioner of Food and Drugs. [FR Doc. 2019–25919 Filed 11–27–19; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2018–E–4429] Determination of Regulatory Review Period for Purposes of Patent Extension; CRYSVITA AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRYSVITA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product. DATES: Anyone with knowledge that any of the dates as published (see the SUPPLEMENTARY INFORMATION section) are incorrect may submit either electronic or written comments and ask for a redetermination by January 28, 2020. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by May 27, 2020. See ‘‘Petitions’’ in the SUPPLEMENTARY INFORMATION section for more information. ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before January 28, 2020. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of January 28, 2020. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery SUMMARY: E:\FR\FM\29NON1.SGM 29NON1
[Pages 65822-65823]
[FR Doc No: 2019-25919]
[Docket No. FDA-2019-D-5255]
Clinical Immunogenicity Considerations for Biosimilar and
Interchangeable Insulin Products; Draft Guidance for Industry;
the availability of a draft guidance for industry entitled ``Clinical
Immunogenicity Considerations for Biosimilar and Interchangeable
Insulin Products.'' The purpose of this draft guidance is to provide
recommendations to applicants regarding whether and when comparative
clinical immunogenicity studies may be needed to support licensure of
proposed biosimilar and interchangeable recombinant human insulins,
recombinant human insulin mix products, and recombinant insulin analog
products that are intended for the treatment of patients with Type 1 or
guidance by January 28, 2020 to ensure that the Agency considers your
FDA-2019-D-5255 for ``Clinical Immunogenicity Considerations for
Biosimilar and Interchangeable Insulin Products.'' Received comments
[[Page 65823]]
must identify this information as ``confidential.'' Any information
FOR FURTHER INFORMATION CONTACT: Sandra Benton, Center for Drug
Hampshire Ave., Bldg. 22, Rm. 1132, Silver Spring, MD 20993, 301-796-
1042; [email protected].
entitled ``Clinical Immunogenicity Considerations for Biosimilar and
Interchangeable Insulin Products.'' The purpose of this draft guidance
is to provide recommendations to applicants regarding whether and when
comparative clinical immunogenicity studies may be needed to support
licensure of proposed biosimilar and interchangeable recombinant human
insulins, recombinant human insulin mix products, and recombinant
insulin analog products that are intended for the treatment of patients
with Type 1 or Type 2 diabetes mellitus (collectively referred to as
``insulin products'').
Innovation Act of 2009 (BPCI Act) requires that on March 23, 2020, an
approved application for a biological product under section 505 of the
Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355) will be
deemed to be a license for the biological product under section 351 of
the Public Health Service Act (PHS Act) (42 U.S.C. 262). Although the
majority of therapeutic biological products have been licensed under
section 351 of the PHS Act, some protein products historically have
been approved under section 505 of the FD&C Act. The BPCI Act clarified
the statutory authority under which certain protein products will be
regulated by amending the definition of a ``biological product'' in
section 351(i) of the PHS Act to include a ``protein (except any
chemically synthesized polypeptide),'' and describing procedures for
submission of a marketing application for certain ``biological
The biological products affected by this transition include insulin
products. On March 23, 2020, the approved new drug applications (NDAs)
for insulin products will be deemed to be licenses under section 351(a)
of the PHS Act. Such deemed BLAs will then be available to be used as
reference products by applicants seeking licensure of proposed
biosimilar and interchangeable insulin products under section 351(k) of
finalized, will represent the current thinking of FDA on ``Clinical
Insulin Products.'' It does not establish any rights for any person and
This draft guidance refers to information collection provisions
under the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. 3501-3521).
The submission of an investigational new drug application is covered
under 21 CFR part 312 and approved under OMB control number 0910-0014.
The submission of a BLA under section 351(a) of the PHS Act is covered
under 21 CFR part 601 and approved under OMB control number 0910-0338.
The submission of a BLA under section 351(k) of the PHS Act is covered
under 21 CFR part 601 and approved under OMB control number 0910-0719.
[FR Doc. 2019-25919 Filed 11-27-19; 8:45 am]